New Option To Support Cervical Health In Women With HPV In Singapore

Colpofix^®, a vaginal spray gel medical device, supports the regression of HPV-related cervical lesions

SINGAPORE, Sept. 21, 2026 /PRNewswire/ -- Women in Singapore now have another option to support their cervical health following Human Papillomavirus (HPV) infection, with DKSH's launch of Colpofix^®. The vaginal spray gel medical device is indicated for the prevention and treatment of cervical lesions caused by HPV.⁴

HPV is one of the most common viral infections worldwide, with one in 10 women in Singapore affected by the infection.¹ A 'wait and see' approach is adopted as most cases clear naturally within one to two years, but when HPV persists, it can lead to cervical cell changes that require medical follow-up and monitoring.² For many women, a 'wait and see' approach can mean living with uncertainty between appointments, unsure what the result means and what happens next and this period can feel like a long wait. Research shows that an abnormal result can also increase psychological stress.³ Women deserve healthcare solutions developed with their needs and experiences in mind.

Colpofix^® gives healthcare professionals and women an additional option during this stage. It acts locally on the cervico-vaginal mucosa and helps control the physiological conditions of the transformation zone.

Clinical studies have reported positive results in the regression of low-grade cervical lesions, restoration and maintenance of the vaginal microbiota, and re-epithelialisation of the cervical mucosa, contributing to an improvement in HPV clearance.^{5, 6, 7, 8} In one study, Colpofix^® demonstrated 95.7% regression of HPV-CIN1 lesions.⁸

Once applied, the medical device sprays a gel that forms a protective film over the cervico-vaginal mucosa. It supports hydration to promote re-epithelialisation and the regression of cervical lesions. It also helps restore and maintain the vaginal microbiota. An ergonomic cannula allows the gel to be applied accurately and distributed evenly without spilling.

"At the heart of DKSH Healthcare's value proposition is a strong focus on patient centricity. We are committed to advancing women's health by ensuring access to effective, science-based solutions that address critical health needs. Bringing Colpofix® to Singapore is part of that commitment, giving women and their healthcare professionals an option to consider together," said Reuben Ong, Vice President, DKSH Singapore.

"Our goal is to provide healthcare solutions that address not only clinical needs but also the emotional well-being of women navigating cervical health concerns. Colpofix^® brings an evidence-based approach to supporting women with HPV-related cervical lesions. said Lionel Tan, Cluster Lead, Own Brands.

Now available in Singapore by prescription, individuals who are interested to find out more about Colpofix^® should consult a healthcare professional for advice on whether the product is appropriate for them.

- END –

References

About DKSH

For more than 160 years, DKSH has been delivering growth for companies in Asia Pacific, Europe, and North America across its Business Units Healthcare, Consumer Goods, Performance Materials, and Technology. As a leading Market Expansion Services provider, DKSH offers sourcing, market insights, marketing and sales, e-commerce, distribution and logistics as well as after-sales services, following its purpose of enriching people's lives. DKSH is a participant of the United Nations Global Compact and adheres to its principles-based approach to responsible business. Listed on the SIX Swiss Exchange, DKSH operates in 35 markets with 26,840 specialists, generating net sales of CHF 11.1 billion in 2025. DKSH Business Unit Healthcare distributes pharmaceuticals, consumer health, over-the-counter products and medical devices. With around 7,580 specialists, the Business Unit generated net sales of CHF 5.8 billion in 2025. www.dksh.com/hec

SOURCE DKSH Healthcare, Singapore